Peroxisome proliferator‑activated receptor γ polymorphisms as risk factors for dyslipidemia

Gu,Shu‑Jun; Guo,Zhi‑Rong; Zhou,Zheng‑Yuan; Hu,Xiao‑Shu; Wu,Ming; Zhang,Ning

doi:10.3892/mmr.2014.2553

Peroxisome proliferator‑activated receptor γ polymorphisms as risk factors for dyslipidemia

Authors:
- Shu‑Jun Gu
- Zhi‑Rong Guo
- Zheng‑Yuan Zhou
- Xiao‑Shu Hu
- Ming Wu
- Ning Zhang
View Affiliations

Affiliations: Center for Disease Control of Changshu, Suzhou, Jiangsu 215500, P.R. China, Department of Epidemiology, School of Public Health, Soochow University, Suzhou, Jiangsu 215123, P.R. China, Health Bureau of Jiangsu Province, Nanjing, Jiangsu 210009, P.R. China, Center for Disease Control of Jiangsu Province, Nanjing, Jiangsu 210009, P.R. China
Published online on: September 10, 2014 https://doi.org/10.3892/mmr.2014.2553
Pages: 2759-2763

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Peroxisome proliferator‑activated receptor γ (PPARγ) may play an important role in lipid metabolism directly or by inducing the transcription of target genes. The aim of the present study was to investigate the association between common variants at the PPARγ locus (C1431T and Pro12Ala polymorphisms) and lipid serum levels. The studied population consisted of 820 subjects randomly selected from the Prevention of Multiple Metabolic Disorders and Metabolic Syndrome in Jiangsu Province cohort population. All subjects were interviewed and blood samples were obtained for laboratory analysis and DNA extraction. The TaqMan single nucleotide polymorphism genotyping assay was used for polymorphism genotyping. Individual polymorphisms and haplotype data were available for analysis. The 12Ala allele was found to be associated with significantly increased levels of triglyceride (TG) (P<0.01), whilst the 1431T allele was found to be associated with significantly increased levels of TG, total cholesterol (TC) and non‑high‑density lipoprotein (non‑HDL) (P<0.01). When P‑C, the most common haplotype, was used as the reference group, the P‑T, A‑C and A‑T haplotypes were found to be associated with significantly increased levels of TG (P<0.01). In addition, the A‑T haplotype was shown to be associated with significantly increased levels of TC and non‑HDL (P<0.01). In conclusion these results suggest that PPARγ gene variability may increase the risk of dyslipidemia.

View Figures

View References

1	Cullen P: Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol. 86:943–949. 2000. View Article : Google Scholar : PubMed/NCBI
2	Azhar S: Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease. Future Cardiol. 6:657–691. 2010. View Article : Google Scholar : PubMed/NCBI
3	Wu MH, Chu CH, Chou YC, Chou WY, Yang T, Hsu GC, Yu CP, Yu JC and Sun CA: Joint effect of peroxisome proliferator-activated receptor γ genetic polymorphisms and estrogen-related risk factors on breast cancer risk: results from a case-control study in Taiwan. Breast Cancer Res Treat. 127:777–784. 2011.
4	Schoonjans K, Staels B and Auwerx J: Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res. 37:907–925. 1996.PubMed/NCBI
5	Chawla A, Barak Y, Nagy L, Liao D, Tontonoz P and Evans RM: PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med. 7:48–52. 2001. View Article : Google Scholar : PubMed/NCBI
6	Swarbrick MM, Chapman CM, McQuillan BM, Hung J, Thompson PL and Beilby JP: A Pro12Ala polymorphism in the human peroxisome proliferator-activated receptor-gamma 2 is associated with combined hyperlipidaemia in obesity. Eur J Endocrinol. 144:277–282. 2001. View Article : Google Scholar
7	Tavares V, Hirata RD, Rodrigues AC, Monte O, Salles JE, Scallissi N, Speranza AC, Gomes S and Hirata MH: Effect of the peroxisome proliferator-activated receptor-gamma C161T polymorphism on lipid profile in Brazilian patients with Type 2 diabetes mellitus. J Endocrinol Invest. 28:129–136. 2005. View Article : Google Scholar : PubMed/NCBI
8	Barbieri M, Rizzo MR, Papa M, Acampora R, De Angelis L, Oliviri F, Marchegiani F, Franceschi C and Paolisso G: Role of interaction between variants in the PPARG and interleukin-6 genes on obesity related metabolic risk factors. Exp Gerontol. 40:599–604. 2005. View Article : Google Scholar : PubMed/NCBI
9	Yilmaz-Aydogan H, Kurnaz O, Kurt O, Akadam-Teker B, Kucukhuseyin O, Tekeli A and Isbir T: Effects of the PPARG P12A and C161T gene variants on serum lipids in coronary heart disease patients with and without Type 2 diabetes. Mol Cell Biochem. 358:355–363. 2011. View Article : Google Scholar : PubMed/NCBI
10	Hu XS, Guo ZR, Zhou H, Shi ZM, Wu M, Zhang J, Sun GX, Zhou ZY, Pan XQ and Yao CL: Study on the prevalence of metabolic syndrome among 35–74 year-olds in Jiangsu province. Zhonghua Liu Xing Bing Xue Za Zhi. 27:751–756. 2006.(In Chinese).
11	Clement K, Hercberg S, Passinge B, Galan P, Varroud-Vial M, Shuldiner AR, Beamer BA, Charpentier G, Guy-Grand B, Froguel P and Vaisse C: The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes. Int J Obes Relat Metab Disord. 24:391–393. 2000. View Article : Google Scholar : PubMed/NCBI
12	Hara K, Okada T, Tobe K, Yasuda K, Mori Y, Kadowaki H, Hagura R, Akanuma Y, Kimura S, Ito C and Kadowaki T: The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun. 271:212–216. 2000. View Article : Google Scholar : PubMed/NCBI
13	Doney A, Fischer B, Frew D, Cumming A, Flavell DM, World M, Montgomery HE, Boyle D, Morris A and Palmer CN: Haplotype analysis of the PPARgamma Pro12Ala and C1431T variants reveals opposing associations with body weight. BMC Genet. 3:212002. View Article : Google Scholar : PubMed/NCBI
14	Iwata E, Matsuda H, Fukuda T, Fukuen S, Motomura T, Igarashi T, Yamamoto I and Azuma J: Mutations of the peroxisome proliferator-activated receptor gamma (PPARgamma) gene in a Japanese population: the Pro12Ala mutation in PPAR gamma 2 is associated with lower concentrations of serum total and non-HDL cholesterol. Diabetologia. 44:1354–1355. 2001. View Article : Google Scholar
15	Tai ES, Corella D, Deurenberg-Yap M, Adiconis X, Chew SK, Tan CE and Ordovas JM: Differential effects of the C1431T and Pro12Ala PPARgamma gene variants on plasma lipids and diabetes risk in an Asian population. J Lipid Res. 45:674–685. 2004. View Article : Google Scholar : PubMed/NCBI
16	Brand-Herrmann SM, Kuznetsova T, Wiechert A, Stolarz K, Tikhonoff V, Schmidt-Petersen K, Telgmann R, Casiglia E, Wang JG, Thijs L, Staessen JA and Brand E: European Project on Genes in Hypertension Investigators: Alcohol intake modulates the genetic association between HDL cholesterol and the PPARgamma2 Pro12Ala polymorphism. J Lipid Res. 46:913–919. 2005. View Article : Google Scholar
17	Pollex RL, Mamakeesick M, Zinman B, Harris SB, Hegele RA and Hanley AJ: Peroxisome proliferator-activated receptor gamma polymorphism Pro12Ala is associated with nephropathy in type 2 diabetes. J Diabetes Complications. 21:166–171. 2007. View Article : Google Scholar : PubMed/NCBI
18	Beamer BA, Yen CJ, Andersen RE, Muller D, Elahi D, Cheskin LJ, Andres R, Roth J and Shuldiner AR: Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes. 47:1806–1808. 1998. View Article : Google Scholar
19	Zhou X, Chen J and Xu W: Association between C1431T polymorphism in peroxisome proliferator-activated receptor-γ gene and coronary artery disease in Chinese Han population. Mol Biol Rep. 39:1863–1868. 2012.
20	Patil N, Berno AJ, Hinds DA, Barrett WA, Doshi JM, Hacker CR, Kautzer CR, Lee DH, Marjoribanks C, McDonough DP, Nguyen BT, Norris MC, Sheehan JB, Shen N, Stern D, Stokowski RP, Thomas DJ, Trulson MO, Vyas KR, Frazer KA, Fodor SP and Cox DR: Blocks of limited haplotype diversity revealed by high-resolution scanning of human chromosome 21. Science. 294:1719–1723. 2001. View Article : Google Scholar : PubMed/NCBI
21	Gu SJ, Guo ZR, Zhou ZY, Hu XS and Wu M: PPAR α and PPAR γ polymorphisms as risk factors for dyslipidemia in a Chinese Han population. Lipids Health Dis. 13:232014.
22	Semple RK, Chatterjee VK and O’Rahilly S: PPAR gamma and human metabolic disease. J Clin Invest. 116:581–589. 2006. View Article : Google Scholar : PubMed/NCBI
23	Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, Laakso M, Fujimoto W and Auwerx J: A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 20:284–287. 1998. View Article : Google Scholar